- Conditions
- Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Multiple Myeloma, Stage III Multiple Myeloma
- Interventions
- bryostatin 1, vincristine sulfate, laboratory biomarker analysis
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1998
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 217–240
of 802
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Chronic Lymphocytic Leukemia
- Interventions
- AT-101
- Drug
- Lead sponsor
- Ascenta Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 1
- States / cities
- San Diego, California
- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
- Interventions
- mycophenolate mofetil, tacrolimus
- Drug
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- Up to 65 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2004
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Lymphoma
- Interventions
- filgrastim, sargramostim, carboplatin, etoposide, ifosfamide, autologous bone marrow transplantation, bone marrow ablation with stem cell support, peripheral blood stem cell transplantation, radiation therapy
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years to 65 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1995 – 2003
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Leukemia
- Interventions
- rituximab, cyclophosphamide, pentostatin, Alemtuzumab
- Biological · Drug
- Lead sponsor
- Eastern Cooperative Oncology Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 102 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2018
- U.S. locations
- 143
- States / cities
- Scottsdale, Arizona • Aurora, Colorado • Boulder, Colorado + 112 more
- Conditions
- Chronic Myeloproliferative Disorders, Fatigue, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Precancerous Condition, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- American ginseng, placebo
- Drug · Other
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 364 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2013
- U.S. locations
- 326
- States / cities
- Scottsdale, Arizona • Aurora, Colorado • Boulder, Colorado + 208 more
- Conditions
- Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Indolent Adult Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma
- Interventions
- Cladribine, Laboratory Biomarker Analysis, Rituximab, Vorinostat
- Drug · Other · Biological
- Lead sponsor
- OHSU Knight Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2017
- U.S. locations
- 2
- States / cities
- Portland, Oregon • Hershey, Pennsylvania
- Conditions
- Hematologic Malignancy
- Interventions
- BBI608, Dexamethasone, Bortezomib, Imatinib, Ibrutinib
- Drug
- Lead sponsor
- Sumitomo Pharma America, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 8
- States / cities
- Denver, Colorado • Indianapolis, Indiana • Germantown, Tennessee + 4 more
- Conditions
- Leukemia, Myelodysplastic Syndromes
- Interventions
- exatecan mesylate
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- Not listed
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2005
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Interventions
- filgrastim, sargramostim, cyclophosphamide, melphalan, autologous bone marrow transplantation, peripheral blood stem cell transplantation, radiation therapy
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1997
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Nonmalignant Neoplasm
- Interventions
- trivalent influenza vaccine, Immunoenzyme technique, Laboratory biomarker analysis
- Biological · Other
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 459 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2013
- U.S. locations
- 2
- States / cities
- Duarte, California • Pasadena, California
- Conditions
- Solid Tumor, Colorectal Cancer, Non Hodgkin Lymphoma, Sarcoma, Chondrosarcoma, Small Lymphocytic Lymphoma, Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia
- Interventions
- Aplitabart (IGM-8444), FOLFIRI, Bevacizumab (and approved biosimilars), Birinapant, Venetoclax, Gemcitabine, Docetaxel, Azacitidine
- Drug
- Lead sponsor
- IGM Biosciences, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 272 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 37
- States / cities
- Phoenix, Arizona • Duarte, California • Los Alamitos, California + 29 more
- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Precancerous/Nonmalignant Condition, Small Intestine Cancer
- Interventions
- anti-thymocyte globulin, filgrastim, cladribine, cyclophosphamide, etoposide, methylprednisolone, tacrolimus, allogeneic bone marrow transplantation, in vitro-treated peripheral blood stem cell transplantation
- Biological · Drug · Procedure
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- Up to 45 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2000
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Chronic Lymphocytic Leukemia
- Interventions
- Campath
- Drug
- Lead sponsor
- Northwell Health
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2009
- U.S. locations
- 1
- States / cities
- New Hyde Park, New York
- Conditions
- Leukemia, Lymphoma
- Interventions
- Pegfilgrastim, Rituximab, Cyclophosphamide
- Biological · Drug
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 94 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2011
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Waldenstrom Macroglobulinemia (WM), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), Follicular Lymphoma (FL), Diffuse Large B-cell Lymphoma (DLBCL), Primary Central Nervous System Lymphoma (PCNSL)
- Interventions
- NX-2127
- Drug
- Lead sponsor
- Nurix Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 248 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 16
- States / cities
- Duarte, California • Orange, California • San Francisco, California + 13 more
- Conditions
- Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- Interventions
- Acalabrutinib (Arm A), Acalabrutinib (Arm B)
- Drug
- Lead sponsor
- Acerta Pharma BV
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2025
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Lymphoma
- Interventions
- estramustine phosphate sodium, paclitaxel
- Drug
- Lead sponsor
- Fox Chase Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1996 – 2006
- U.S. locations
- 17
- States / cities
- Flemington, New Jersey • Lakewood, New Jersey • Millville, New Jersey + 14 more
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Precancerous Condition
- Interventions
- therapeutic allogeneic lymphocytes, busulfan, cyclosporine, fludarabine phosphate, mycophenolate mofetil, peripheral blood stem cell transplantation, Total Body Irradiation (TBI), Granulocyte colony-stimulating factor (G-CSF), Phenytoin, Methotrexate
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- OHSU Knight Cancer Institute
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 147 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2015
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Refractory Chronic Lymphocytic Leukemia, Refractory Small Lymphocytic Lymphoma
- Interventions
- Trabectedin, Venetoclax
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
- Interventions
- sargramostim
- Biological
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- 5 Years to 60 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2002
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Chronic Lymphocytic Leukemia
- Interventions
- Ofatumumab + Fresh Frozen Plasma
- Drug
- Lead sponsor
- Joseph Tuscano
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2020
- U.S. locations
- 1
- States / cities
- Sacramento, California
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
- Interventions
- alemtuzumab, therapeutic allogeneic lymphocytes, fludarabine phosphate, melphalan, tacrolimus, thiotepa, peripheral blood stem cell transplantation
- Biological · Drug · Procedure
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Melanoma, Myelodysplastic Syndrome, Multiple Myeloma, Lymphoma
- Interventions
- Tissue Registry Study
- Other
- Lead sponsor
- SCRI Development Innovations, LLC
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee